Successful treatment of steroid-refractory hepatitic variant of
liver graft-vs-host disease with pulse cyclophosphamide

J 2009

Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide

MAYER, Jiří, Marta KREJČÍ, Zdeněk POSPÍŠIL, Michael DOUBEK, Andrea JANÍKOVÁ et. al.

Základní údaje

Originální název

Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide

Název česky

Úspěšná léčba steroid-refraktorní hepatitické varianty jaterní GvHD cyclophosphamidovými pulsy

Autoři

MAYER, Jiří (203 Česká republika, garant, domácí), Marta KREJČÍ (203 Česká republika, domácí), Zdeněk POSPÍŠIL (203 Česká republika, domácí), Michael DOUBEK (203 Česká republika, domácí), Andrea JANÍKOVÁ (203 Česká republika, domácí), Daniela ŽÁČKOVÁ (203 Česká republika, domácí), Zdeněk RÁČIL (203 Česká republika, domácí), Lenka ŠMARDOVÁ (203 Česká republika, domácí), Milan NAVRÁTIL (203 Česká republika, domácí) a Jan KAMELANDER (203 Česká republika, domácí)

Vydání

Experimental Hematology, Elsevier, 2009, 0301-472X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.106

Kód RIV

RIV/00216224:14110/09:00067130

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.exphem.2009.03.006

UT WoS

000266458200012

Klíčová slova anglicky

STEM-CELL TRANSPLANTATION; BONE-MARROW TRANSPLANTATION; DONOR LYMPHOCYTE INFUSION; ANTI-THYMOCYTE GLOBULIN; ACUTE GVHD; RETROSPECTIVE ANALYSIS; THERAPY; BLOOD

Štítky

ACUTE GVHD, ANTI-THYMOCYTE GLOBULIN, BLOOD, BONE-MARROW TRANSPLANTATION, DONOR LYMPHOCYTE INFUSION, RETROSPECTIVE ANALYSIS, STEM-CELL TRANSPLANTATION, THERAPY

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 4. 2014 10:49, Ing. Mgr. Věra Pospíšilíková

Anotace

ORIG CZ

V originále

Objective. Corticosteroid-resistant graft-vs-host disease (GVHD) is difficult to manage and is associated with high morbidity and mortality. No standard treatment exists. We have previously seen good results with pulse cyclophosphamide (Cy) in the treatment of liver GVHD in contrast to gastrointestinal GVHD, and here we report results of pulse Cy protocol in the treatment of steroid-refractory hepatitic variant of liver GVHD, with no association to the gut. Materials and Methods. Cy was infused at a dose of 1,000 mg/m(2). Twenty-nine cyclophosphamide administrations were given to 21 patients. Median time of GVHD onset and Cy administration after transplantation, or donor lymphocyte infusion, were 58 and 69 days, respectively. Results. Eleven patients (52%) achieved complete remission and 6 patients (29%) achieved partial remission. Four patients (19%) did not respond, however, their condition stabilized and, upon additional therapy, three achieved partial remission and one complete remission. Overall survival of all 21 patients is 86%, with median and maximal follow-up of 33 and 81 months, respectively. Toxicity was mild and easily manageable without influencing chimerism or disease status. Conclusions. Pulse Cy seems to be an effective treatment for steroid-refractory hepatitic variant of liver GVHD with a good toxicity profile, which may favor its use instead of drugs with more pronounced immunosuppressive effects.

Česky

Pulsní Cy se ukazuje jako účinný prostředek při léčbě jaterní GvHD.

Návaznosti

MSM0021622430, záměr

Název: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Citovat

MAYER, Jiří, Marta KREJČÍ, Zdeněk POSPÍŠIL, Michael DOUBEK, Andrea JANÍKOVÁ, Daniela ŽÁČKOVÁ, Zdeněk RÁČIL, Lenka ŠMARDOVÁ, Milan NAVRÁTIL a Jan KAMELANDER. Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide. Experimental Hematology. Elsevier, 2009, roč. 37, č. 6, s. 767-773. ISSN 0301-472X. Dostupné z: https://dx.doi.org/10.1016/j.exphem.2009.03.006.

@article{837827,
   author = {Mayer, Jiří and Krejčí, Marta and Pospíšil, Zdeněk and Doubek, Michael and Janíková, Andrea and Žáčková, Daniela and Ráčil, Zdeněk and Šmardová, Lenka and Navrátil, Milan and Kamelander, Jan},
   article_number = {6},
   doi = {http://dx.doi.org/10.1016/j.exphem.2009.03.006},
   keywords = {STEM-CELL TRANSPLANTATION; BONE-MARROW TRANSPLANTATION; DONOR LYMPHOCYTE INFUSION; ANTI-THYMOCYTE GLOBULIN; ACUTE GVHD; RETROSPECTIVE ANALYSIS; THERAPY; BLOOD},
   language = {eng},
   issn = {0301-472X},
   journal = {Experimental Hematology},
   title = {Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide},
   volume = {37},
   year = {2009}
}

TY  - JOUR
ID  - 837827
AU  - Mayer, Jiří - Krejčí, Marta - Pospíšil, Zdeněk - Doubek, Michael - Janíková, Andrea - Žáčková, Daniela - Ráčil, Zdeněk - Šmardová, Lenka - Navrátil, Milan - Kamelander, Jan
PY  - 2009
TI  - Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide
JF  - Experimental Hematology
VL  - 37
IS  - 6
SP  - 767-773
EP  - 767-773
PB  - Elsevier
SN  - 0301472X
KW  - STEM-CELL TRANSPLANTATION
KW  - BONE-MARROW TRANSPLANTATION
KW  - DONOR LYMPHOCYTE INFUSION
KW  - ANTI-THYMOCYTE GLOBULIN
KW  - ACUTE GVHD
KW  - RETROSPECTIVE ANALYSIS
KW  - THERAPY
KW  - BLOOD
N2  - Objective. Corticosteroid-resistant graft-vs-host disease (GVHD) is difficult to manage and is associated with high morbidity and mortality. No standard treatment exists. We have previously seen good results with pulse cyclophosphamide (Cy) in the treatment of liver GVHD in contrast to gastrointestinal GVHD, and here we report results of pulse Cy protocol in the treatment of steroid-refractory hepatitic variant of liver GVHD, with no association to the gut. Materials and Methods. Cy was infused at a dose of 1,000 mg/m(2). Twenty-nine cyclophosphamide administrations were given to 21 patients. Median time of GVHD onset and Cy administration after transplantation, or donor lymphocyte infusion, were 58 and 69 days, respectively. Results. Eleven patients (52%) achieved complete remission and 6 patients (29%) achieved partial remission. Four patients (19%) did not respond, however, their condition stabilized and, upon additional therapy, three achieved partial remission and one complete remission. Overall survival of all 21 patients is 86%, with median and maximal follow-up of 33 and 81 months, respectively. Toxicity was mild and easily manageable without influencing chimerism or disease status. Conclusions. Pulse Cy seems to be an effective treatment for steroid-refractory hepatitic variant of liver GVHD with a good toxicity profile, which may favor its use instead of drugs with more pronounced immunosuppressive effects.
ER  -

MAYER, Jiří, Marta KREJČÍ, Zdeněk POSPÍŠIL, Michael DOUBEK, Andrea JANÍKOVÁ, Daniela ŽÁČKOVÁ, Zdeněk RÁČIL, Lenka ŠMARDOVÁ, Milan NAVRÁTIL a Jan KAMELANDER. Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide. \textit{Experimental Hematology}. Elsevier, 2009, roč.~37, č.~6, s.~767-773. ISSN~0301-472X. Dostupné z: https://dx.doi.org/10.1016/j.exphem.2009.03.006.

Podrobný výpis o publikaci